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Abstract 
BET proteins are epigenetic readers whose deregulation results in cancer and inflammation. We show 
that BET proteins (BRD2, BRD3, BRD4 and BRDT) are globally similar with subtle differences in the 
sequences and structures of their N-terminal bromodomain. Principal component analysis and non-
negative matrix factorization reveal distinct structural clusters associated with specific BET family 
members, experimental methods, and source organisms. Subtle variations in structural dynamics are 
evident in the acetylated lysine (Kac) binding pocket of BET bromodomains. Using multiple structural 
clustering methods, we have also identified representative structures of BET proteins, which are 
potentially useful for developing potential therapeutic agents. 
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1 Introduction 
In eukaryotic cells, transcription is a tightly and spatiotemporally regulated process that relies on 
the transient and non-obligated protein complexes. The formations of these complexes are regulated 
by post-translational modifications such as ε-N-acetylation of lysine residues. Aberrant regulation of 
acetylation levels is associated with a wide array of diseases including cancer, inflammation and viral 
infection [1].  
In the nucleus, lysine acetylations of histone proteins are associated with transcriptional activation 
of genes, yet the molecular mechanisms and functions remain largely elusive. The molecular players 
include the following proteins: writers (such as histone acetyltransferases), erasers (histone 
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deacetylases) and readers of epigenetic marks and epigenetic memory, in which epigenetics are 
heritable alterations in gene expression that are not due to the change in DNA sequence and have been 
shown to affect several generations of offspring [2].  
While the epigenetic-associate proteins have emerged as attractive anti-cancer targets, efforts to 
obtain comprehensive understanding of their molecular mechanisms and functions necessitate multiple 
structural analysis as a prerequisite for optimum structure-based development of therapeutic agents. In 
this study, we focus on structural dynamics of the readers, particularly chromatin-modifying 
bromodomains, which are the only known protein recognition module that selectively recognizes and 
binds ε-N-acetylated lysine (Kac) [3].  
Human genome encodes for at least 46 different proteins that contain a total of 61 bromodomains, 
due the presence of multiple (up to six) bromodomains in some proteins [4]. These 61 bromodomains 
have been clustered into eight distinct families, based on their large sequence variations [5]. To 
systematically apply existing and recent structural clustering methods, we focus on the bromo and 
extra terminal (BET) family because this family has the largest number of experimental structures 
among the eight families.  
BET family consists of BRD2, BRD3, BRD4, and BRDT. Their structure comprises two 
bromodomains, an extra terminal domain, and a C-terminal recruitment domain. Bromodomains adopt 
an all-alpha protein fold, a bundle of four alpha helices each separated by loop regions of variable 
lengths. BET proteins can also bind to multiple neighboring Kac marks with a single pocket [6], with 
enhanced affinity [7] and/or simultaneously [5] by utilizing multiple bromodomains that possibly twist 
like the immunoglobulin domains do at their linkers [8], suggesting cooperativity and allostery as 
possible molecular mechanisms of BET proteins. During mitosis, BET proteins are recruited to 
transcriptional start sites [9]. Since BET proteins regulate the transcription of oncogenes, growth-
promoting and anti-apoptotic genes, the BET bromodomains possessing druggable Kac binding 
pocket, are attractive targets for the design and development of potential therapeutic drugs [10] in the 
form of small molecules [11] (such as JQ1 [10], a nanomolar inhibitor [12] that targets the BET 
bromodomains) or stabilized peptides (such as cyclic peptides [13] or stapled peptides). These BET 
inhibitors disrupt the interactions between BET and its acetylated binding partners, such as histones 
(H3 and H4) [14], the N-terminal domain of androgen receptor (whose signaling is deregulated in 
castration-resistant prostate cancer [15]), RelA subunit of inflammation-associated NF-κB [16]. Since 
protein structures are not static but intrinsically dynamic [17], we aim to utilize multiple 
experimentally available structures of BET bromodomains to investigate the structural dynamics of 
these epigenetic reader modules and its Kac pocket. 
2 Materials and Methods 
To characterize the structural dynamics of BET N-terminal bromodomains, we have performed 
structural clustering using root mean square deviation (RMSD), principal component analysis (PCA) 
and non-negative matrix factorization (NMF). Structures were visualized using PyMOL and VMD. 
2.1 Structural data   
To perform systematic multiple structural analysis similarly, we first retrieved the structural data of 
the BET proteins from the Protein Data Bank (PDB). As of January 2015, no full-length structure of 
any BET family member is available, but there are 118 PDB entries for BET N-terminal 
bromodomain. Their PDB codes are 1X0J, 2DVQ, 2DVR, 2DVS, 2L5E, 2NXB, 2OSS, 2RFJ, 2WP2, 
2YDW, 2YEK, 2YEL, 2YW5, 3AQA, 3JVJ, 3JVK, 3MUK, 3MUL, 3MXF, 3P5O, 3S91, 3SVF, 
3SVG, 3U5J, 3U5K, 3U5L, 3UVW, 3UVX, 3UVY, 3UW9, 3ZYU, 4A9E, 4A9F, 4A9H, 4A9I, 4A9J, 
4A9L, 4A9M, 4A9N, 4A9O, 4AKN, 4ALG, 4ALH, 4BJX, 4BW1, 4BW2, 4BW3, 4BW4, 4C66, 
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4C67, 4CFK, 4CFL, 4DON, 4E96, 4F3I, 4FLP, 4GPJ, 4HBV, 4HBW, 4HBX, 4HBY, 4HXK, 4HXL, 
4HXM, 4HXN, 4HXO, 4HXP, 4HXR, 4HXS, 4IOO, 4IOQ, 4IOR, 4J0R, 4J0S, 4J3I, 4KCX, 4KV1, 
4LR6, 4LRG, 4LYI, 4LYS, 4LYW, 4LZR, 4LZS, 4MEN, 4MEO, 4MEP, 4MEQ, 4MR3, 4MR4, 
4NQM, 4NR8, 4NUC, 4NUD, 4NUE, 4O70, 4O71, 4O72, 4O74, 4O75, 4O76, 4O77, 4O78, 4O7A, 
4O7B, 4O7C, 4O7E, 4O7F, 4OGI, 4OGJ, 4PCE, 4PCI, 4PS5, 4QZS, 4UYD, 4UYF, 4UYH, 4WIV. 
For detailed studies of multiple structures similar to those performed on other proteins such as Ras 
protein [18], we generated an ensemble of multiple bromodomain structures of BRD2, BRD3, BRD4 
and BRDT, and another ensemble of BRD4 only bromodomain structures, for subsequent analyses.  
2.2 Structural clustering and non-negative matrix factorization (NMF) 
To analyze the ensembles of BET bromodomain structures, we carried out pairwise RMSD 
calculation, PCA and NMF.  RMSD- and PCA-based clustering also enabled us to identify the 
ensemble-clustroid (the structure with the least divergence to the rest of the structures) and the 
representative structure for each cluster within ensembles. 
In contrast to PCA that learns holistic, not parts-based representations, NMF is an unsupervised, 
parts-based machine learning method. NMF involves the decomposition of a non-negative matrix V 
into two non-negative matrices, W and H. NMF is based on the assumption that parts are collections 
of input elements that can be added together in different combinations representing the whole object of 
interest / dataset [19]. The parts produced by NMF imply subsets of elements that tend to cluster 
together in sub-portion of the object / dataset [20]. A parts-based model provides both an efficient 
representation of the dataset and a potential tool to learn relationships between the parts.  
In our study, we have applied NMF using a multiplicative-updates algorithm [21] to analyze the 
structural dynamics of bromodomain of BET proteins. The multiplicative-updates algorithm starts 
with random initial values for W and H and simultaneously updates the two sub-matrices using 
multiplicative rules iteratively until reaching a convergence to a local minimum.  During the iterative 
update, a Poisson random variable ε is added to represent Poisson noise [22].  
3 Results and Discussion 
3.1 BRD2, BRD3, BRD4 and BRDT are globally similar with subtle 
differences in the structures of their N-terminal bromodomain. 
To examine the structure of BET N-terminal bromodomains in relation to other available 
experimental structures, we first selected the PDB entry 4NUD, which has the best resolution (1.20 Å) 
for BRD4 structure hitherto, as a query to retrieve all experimentally available structures of BET 
proteins. We performed NCBI BLASTp on the 4NUD sequence (residues N44-T166) against the PDB 
database, using a cutoff of 131 as the negative log of Evalue. We used the results of 118 structures to 
form Ensemble 220, consisting of 58 BRD2, 43 BRD3, 110 BRD4 and 9 BRDT N-bromodomain 
structures.  
Multiple sequence alignment (using the N-terminal bromodomain sequences of UniProt entries 
P25440, Q15059, O60885, Q58F21, Q8K2F0, and Q9ESU6) and structural superposition of the 
Ensemble 220 suggest high degree of global similarity and conservation among BRD2, BRD3, BRD4 
and BRTD bromodomains in terms of sequences and structures. To perform structural superposition 
for subsequent PCA, we first identified 57 positions as core residues of the BET N-bromodomain; 
these residues form the most invariant region in the aligned structures of the Ensemble 220. Next, we 
measured the structural distances within the Ensemble 220 using pairwise RMSD. In overall, the 
median and mean pairwise RMSDs are 0.651 Å and 0.903±0.705 Å, respectively. These RMSD values 
are considered to be small and suggest the high similarity between most protein structures within the 
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Ensemble 220.  The maximum pairwise RMSD is 4.849 Å between the 20th model of PDB entry 
2YW5 (a human BRD3) and 2RFJ_A (a human BRDT). We have also used RMSD-based clustering 
to identify the clustroid structure, i.e. the structure with the least divergence to the rest of the structures 
in Ensemble 220, which is 4BW1_A (Figure 1). This structure was resolved in a complex with the 
small molecule S5B, which is a naphthyridines derivative [23]. 
  The histogram of pairwise RMSDs of Ensemble 220 shows three peaks, suggesting a possibility of 
three structural clusters. Nevertheless, the heat map of pairwise RMSDs of Ensemble 220 (Figure 2A) 
suggests at least four structural clusters. Setting the number of cluster to four, we analyzed the clusters 
within Ensemble 220 and observed that the NMR structures from PDB entries 2L5E and 2YW5 
(mouse BRD4 and human BRD3, respectively) were clustered into two distinct groups that contain no 
X-ray crystallographic structures. Structural differences due to experimental methods have also been 
prominently observed in other proteins such as p53 DNA binding domain [24], and the 
methodological effects appear to be more obvious than effects due to different organisms or the 
presence of some mutations. The smallest cluster of the four RMSD-based clusters of Ensemble 220 
contains human BRDT structures. The RMSD-based clustering result also hints that BRD2 and BRD4 
are similar in their bromodomain structures. For the four RMSD-based clusters of Ensemble 220, the 
representative structures are 4BW1_A (a human BRD4), 2RFJ_A (a human BRDT), the 16th model of 
2L5E (a mouse BRD3) and the 14th model of 2YW5 (a human BRD3).  
 
Figure 1: The primary, secondary and tertiary structure of the N-terminal bromodomain of a BET protein (human 
BRD4, residues 75-147, according to UniProt O60885). The tertiary structure of the clustroid of Ensemble 220 
(PDB entry 4WB1) is represented in surface and cartoon; both are in the same orientation. In the surface 
representation, the binding site is occupied by a small molecule S5B [23]. Secondary structures of ჴǦhelices ჴZ, 
ჴA, ჴB and ჴC are colored in blue, green, orange, and red, respectively.  
 
Since Ensemble 220 contains all members of BET, we also created Ensemble 110, which contains 
only BRD4 structures. Ensemble 110 is simply a subset of the Ensemble 220. As expected, the values 
of the median (0.485 Å) and mean (0.491±0.177 Å) of all pairwise RMSDs of Ensemble 110 are lower 
than those of Ensemble 220, reflecting the increasing structural divergence of the latter. The maximum 
pairwise RMSD is between the 3UVY_A and 3UVW_A of modest 1.112 Å. The histogram of 
pairwise RMSDs of Ensemble 110 with a single peak, suggests high structural similarity among BRD4 
bromodomain structures, though subtle variations exist (Figure 2B). The PDB structure 4BW4_A is 
identified as the clustroid of Ensemble 110 in accordance to RMSD-based clustering. Similar to the 
clustroid of Ensemble 220, the clustroid of Ensemble 110 was resolved in a complex with a 
naphthyridines derivative 9B6, but this small molecule has lower IC50 (630 nM) than that of S5B 
(1260 nM) [23]. 
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Figure 2: Heat maps of RMSD-based clustering of (A) Ensemble 220, (B) Ensemble 110 and (C) pocket RMSDs. 
3.2 Dominant principal components show distinct structural clusters 
associated with experimental methods and source organisms. 
To characterize inter-structural relationships of BET bromodomain, we project structures of 
Ensemble 220 onto the first three principal components (PC) with the largest variance (or total mean-
square displacement) of atomic positional fluctuations (Figure 3). Over 81.0% of the variance was 
captured in the first three dominant principal components, and over 74.3% in the first two dominant 
principal components. The first principal component separates not only NMR and crystallographic 
structures, but also separates mouse and human structures of BRD3 bromodomains. The second 
principal component also separates mouse and human structures of BRD3 bromodomains. The third 
principal component separates BRD2 and BRD4 structures, with few minor overlaps. The plane of the 
second and third principal components shows NMR structures occupying the conformational space 
surrounding that of crystallographic structures, with an exception for the crystallographic human 
BRDT structures from the PDB entry 2RFJ, which contribute to the largest pairwise RMSD of 
Ensemble 220.  This consensus result from both RMSD and PCA analysis highlights the uniqueness of 
2RFJ structures. Interestingly, while mouse BRDT structure is unavailable, mouse BRDT 
preferentially recognize peptides with diacetylated lysines, but not monoacetylated ones [7].  
Previous PCA on other proteins, such as p53 DNA binding domain [24], also showed distinct 
clusters for NMR and crystallographic structures. Our PCA observation agrees with the notion that 
NMR structures are more flexible and sample wider conformational space than crystallographic 
structures. Crystallographic conditions such as intermolecular crystal packings might have shift the 
equilibrium of the crystal structures [25].  
 
Figure 3: Analysis of principal components (PC) on the bromodomain structures of BRD2 (magenta), BRD3 
(cyan) BRD4 (black), BRDT (brown) within Ensemble 220. NMR structures are labeled with x. Mouse structures 
are labeled with inverted triangles. 
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Figure 4: Structural dynamics of the bromodomain of BET proteins. Secondary structures of ჴǦhelices ჴZ, ჴA, 
ჴB and ჴC are colored / indicated in blue, green, orange, and red, respectively. (A) Interpolated structures of the 
bromodomain of BET proteins along the first principal component of Ensemble 220. (B) The experimentally-
determined B-factor values of 4BW1_A structure. (C) The residual contribution of the first principal component 
(PC1) represents the dominant dynamics of individual residues. 
 
Using dominant PCA-based clustering, we obtained similar clusters as those of RMSD-based 
clustering and identified cluster-representative structures, in which each representative structure is the 
clustroid of each cluster in Ensemble 220. The representative structures are 4HXR_A (a human 
BRD4), 2RFJ_C (a human BRDT), the 10th model of 2L5E (a mouse BRD3) and the 20th model of 
2YW5 (a human BRD3).  
3.3 BET bromodomains share common structural fold but have 
structurally dynamic Kac binding pocket 
Based on the trajectory that interpolates between the most dissimilar structures in the distribution 
along the first dominant principal component of Ensemble 220 (Figure 4A), we observe that the 
structural scaffold of the bromodomains is largely conserved. On the other hand, it is interestingly 
apparent that both loop ZA (connecting the helices ჴZ and ჴA) and loop BC (connecting the helices 
ჴB and ჴC) contribute to the local diversity of the BET bromodomains structure. This observation 
also reflects the role of both loops in lining the Kac binding site (also termed as binding pocket) and 
possibly rendering substrate specificity [5] through subtle differences in the pocket structure, as 
captured through PCA. Subtle structural differences may result in significant differences in structural 
dynamics, and hence affect functions, as shown in other proteins such as Ras mutants [18]. Subtle 
structural changes such as a flip of a histidine residue into the Kac binding site [11] can pack against 
specific natural ligands or competitive inhibitors to render selectivity. An understanding of the 
structural dynamics of the pocket structures is essential for protein engineering and design of potential 
therapeutic agents such as small molecules and stabilized peptides.  
We compared the residue flexibility (as reflected by the B-factor values) of the clustroid structure 
of Ensemble 220 (Figure 4B) and the individual residue dynamics captured by the first dominant 
principal component (Figure 4C). The B-factor values of 4BW1_A suggest high flexibility of the loop 
BC, but the flexibility of loop ZA is only slightly higher yet comparable to the several residues of 
helices ჴZ and ჴC. However, the residue dynamics captured by the first principal component of 
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multiple structures in Ensemble 220, highlights that the loop ZA is the most flexible region within the 
BET bromodomain. The flexibility of the loop BC is comparable to that of loop AB. Moreover, the 
conserved helices ჴZ, ჴA, ჴB and ჴC are relatively invariant in position, suggesting their roles in 
preserving the structural fold.  
To examine the Kac binding pocket in more details, we calculated pocket RMSDs of all structures 
in Ensemble 220. To define the residues forming the Kac binding pocket, we could examine residues 
around the small molecules, which bind to bromodomains present in Ensemble 220 and selected a 
union of all identified residues. For example, residues W81-F83, Q85, V87, L92, L94, Y97, C136, 
Y139, N140, D145, I146 and V149 of human BRD4 are within 5 Å from the small molecule S5B, 
which was resolved in a complex with the centroid structure of Ensemble 220. An exhaustive way is 
to include all residues forming the loops ZA and BC as residues that define Kac binding site for the 
pocket RMSDs calculations. Using the exhaustive method, for all the pairwise pocket RMSDs within 
Ensemble 220, the median and mean values are 0.477 Å and 0.507±0.201 Å, respectively. The 
maximum pocket RMSD is 1.212 Å between the 4th NMR model of PDB entry 2L5E (a mouse 
BRD3) and 2DVS_C (a human BRD2).  
We plotted the clustering heat map of pocket RMSDs (Figure 2C) and it appears that higher 
number of clusters (than all-residue pairwise RMSDs) is evident in terms of subtle structural diversity. 
By setting the number of cluster to eight, as implied by the distinct boxes along the heat map diagonal, 
we identified a representative structure for each cluster based on pocket RMSDs. The representative 
structures include 4A9E_B (a human BRD2), 4UYH_C (a human BRD2), 2L5E08 (a mouse BRD3), 
4O7A_A (a human BRD4), 4HXS_A (a human BRD4), 2YW504 (a human BRD3), 4O76_A (a 
human BRD4), and 4KCX_A (a human BRDT). The representative structures can then be used as 
initial structures for systematic classification of specific ligands of bromodomains (which is lacking 
hitherto [4]), molecular dynamics simulations (to enhance the conformational space being sampled) 
[26], identification of allosteric sites through fragment mapping [27], normal mode analysis [28], or 
virtual screening based on ensemble docking.  
The acetylation of lysine residue residues neutralizes the positive charge of the primary amine. 
Consequently, the acetylated lysine binding sites on bromodomains must be predominantly 
hydrophobic and deep, to accommodate the acetylated lysine. Such binding sites are attractive pockets 
where competitive inhibitors of Kac, such as Kac mimetic inhibitors, can bind to and block the 
recognition of Kac on histone or non-histone proteins. Hydrophobicity, electrostatic properties, 
network of hydrogen bonds, network of water molecules [29], dynamical volume size and surface 
areas of the binding pocket must be considered in the efforts of drug design, to achieve higher 
specificity and selectivity with minimal side effects. For example, the conserved asparagine (residue 
N156 in human BRD2, N116 in human BRD3, N140 in human BRD4 and N109 in human BRDT) 
forms a hydrogen bond with the natural ligand Kac [30], hence the competitive inhibitors can be 
designed to better utilize this hydrogen bond for anchoring to the Kac binding pocket. Electrostatic 
attractions of the region surrounding the Kac binding pocket have been reported to influence the 
affinity of the bromodomain of Fetal Alzheimer antigen (FALZ) for its binding partner histone H4 [5]. 
Potential allosteric sites that regulate the Kac binding pocket through correlated motions and are 
present only transiently or in a specific member of BET proteins, might also be identified as 
performed on other proteins such as Ras for lead generation [31]. Unlike the Kac binding pocket that 
must preserve its predominantly hydrophobic residues to accommodate Kac, allosteric sites are under 
less evolutionary pressure to remain conserved.  
3.4 Non-negative matrix factorization shows similar clustering results 
as PCA does.  
To further unravel the relationships among the bromodomain structures in Ensemble 220 in terms 
of structural dynamics, we performed non-negative matrix factorization (NMF) to obtain structural 
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clusters of BET proteins (Figure 5) by accounting for parts-based representations, which might have 
been missed in PCA. NMF is a popular method for image analyses (e.g. facial pattern recognition) and 
text mining / natural language processing [21]. In the field of computational biology, NMF has been 
successfully applied to compare and predict classes in microarray data, to discover molecular pattern, 
to functionally characterize genes [22], to predict protein-protein interactions using NMF-based matrix 
completion method [32]. Efforts to popularize the NMF method in analyzing biological data also 
include the developments of LS-NMF [33] and bioNMF [20]. These two methods are mainly for gene 
expression / microarray data analyses, for example to link functionally related genes. In this study, we 
have shown that NMF is also useful to cluster multiple protein structures.  
 
Figure 5:  Non-negative matrix factorization (NMF) analysis of BRD2 (magenta), BRD3 (cyan) BRD4 (black), 
BRDT (brown) structures within Ensemble 220. The x and y axes correspond to two respective columns of matrix 
W.  NMR structures are labeled with x. Mouse structures are labeled with inverted triangles. 
 
Factors 1 and 3 separate NMR and crystallographic structures. Several panels (including those 
between Factors 2 and 3, Factors 2 and 4, Factors 3 and 4) clearly separate mouse BRD3 structures 
from other structures.  Factors 2 and 4 also distinguish BRD2 and BRD4 structures, with minor 
overlaps. In overall, NMF results are similar to the PCA ones, yet NMF is able to capture some subtle 
relationships not obvious in PCA. For example, in the panel between Factors 3 and 4, the human 
BRDT structures from the PDB entry 2RFJ appear to be closer (in terms of structural similarity) to the 
largest cluster containing BRD2 and BRD4 structures, than the mouse BRD3 structures do.  
4 Conclusion 
We have identified subtle differences in the structural dynamics of BET proteins that might have 
non-subtle functional effects. For future studies, we plan to perform large-scale virtual screening using 
National Cancer Institute and ZINC compound libraries against the representative structures identified 
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in this study and cell-based assays to verify the screening results. Future availability of more structures 
facilitated by methods such as high throughput crystallography, will mutually benefit our current and 
other approaches [34] to assign cluster-based functional annotations and recommend strategies for 
developing therapeutic agents targeting bromodomains. 
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